Drug – bio-affecting and body treating compositions – Lymphokine – Interferon
Reexamination Certificate
2006-01-03
2006-01-03
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Lymphokine
Interferon
Reexamination Certificate
active
06982081
ABSTRACT:
A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2′,5′-oligoadenylate synthetase.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4766068 (1988-08-01), Oeda et al.
patent: 4769238 (1988-09-01), Rutter et al.
patent: 5942223 (1999-08-01), Bazer et al.
patent: 6372206 (2002-04-01), Soos et al.
patent: WO 94/10313 (1994-05-01), None
patent: WO96/35789 (1996-11-01), None
patent: WO00/78266 (2000-12-01), None
Kondili et al (Journal of Viral Hepatitis 7:184-195, 2000).
Arase et al (Journal of Gastroenterology 35:221-225, 2000).
Zielinska et al. Archivum immunologiae et therapiae experimentalis (Poland) 1996, 44 (5-6) p. 359-66 (abstract only cited).
Zielinska et al. Archivum immunologiae et therapiae experimentalis (Poland) 1993, 41 (3-4) p. 253-7 (abstract only cited).
Bartol, F.F., et al., “Characterization of proteins produced in vitro by bovine endometrial explants”Biology of Reproduction, 33:745-759 abstract only (1985).
Bazer, F.W. and Johnson, H.M., “Type I Conceptus Inferferons: Maternal Recognition of Pregnancy Signals and Potential Therapeutic Agents”AJRI, 26:19-22 (1991).
Choo, Q.-L., et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome”Science, 244:359-362 (1989).
Choo, Q.-L., et al., “Genetic organization and diversity of the hepatitis C virus”Proc. Natl. Acad. Sci. USA, 88:2451-2455 (1991).
Cotler, S.J., et al., “Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for heaptitis C”Journal of Viral Hepatitis, 7:211-217 (2000).
Cross, J.C., et al., “Constitutive and trophoblast-specific expression of a class of bovine interferon genes”Proc. Natl. Acad. Sci. USA, 88:3817-3821 (1991).
Dieperink, E., et al., “Neurophychiatric Symptoms Associated With Hepatitis C and Interferon Alpha: A Review”Am. J. Psychiatry, 157:867-876 (2000).
Ecker, D.J., et al., “Increasing Gene Expression in Yeast by Fusion to Ubiquitin”Journal of Biological Chemistry, 264(13):7715-7719 (1989).
Gnatek, G.G., et al., “Maternal Recognition of Pregnancy in the Goat: Effects of Conceptus Removal on Interestrus Intervals and Characterization of Conceptus Protein Production during Early Pregnancy”Biology of Reproduction, 41:655-663 (1989).
Helmer, S.D., et al., “Identification of bovine trophoblast protein-1, a secretory protein immunologically related to ovine trophoblast protein-1”J. Reprod. Fert., 79:83-91 (1987).
Imakawa, K., et al., “Interferon-like sequence of ovine trophoblast protein secreted by embryonic trophectoderm”Nature, 330:377-379 (1987).
Imakawa, K., et al., “Molecular Cloning and Characterization of Complementary Deoxyribonucleic Acids Corresponding to Bovine Trophoblast Protein-1: A Comparison with Ovine Trophoblast Protein-1 and Bovine Interferon-αII”Molecular Endocrinology, 3:127-139 (1989).
Jarpe, M.A., et al., “Predicted structural motif of IFNτ”Protein Engineering, 7(7):863-867 (1994).
Jiménez-Sáenz, M., et al., “Sustained response to combination therapy in a patient with chronic hepatitis C and thrombocytopenia secondary to α-interferon”Journal of Gastroenterology and Hepatology, 15:567-569 (2000).
Magrin, S., et al., “Hepatitis C Viremia in Chronic Liver Disease: Relationship to Interferon-α or Corticosteroid Treatment”Hepatology, 19:273-279 (1994).
Ott, T.L., et al., “Cloning and Expression inSaccaromyces cerevisiaeof a Synthetic Gene for the Type-I Trophoblast Interferon Ovine Trophoblast Protein-1: Purification and Antiviral Activity”Journal of Interferon Research, 11:357-364 (1991).
Pawlotsky, J.-M., et al., “Activity of the Interferon-Induced 2′,5′-Oligoadenylate Synthetase in Patients with Chronic Hepatitis C”Journal of Interferon and Cytokine Research, 15:857-862 (1995).
Roberts, R.M., et al., “Interferons as Hormones of Pregnancy”Endocrine Review, 13(3):432-452 (1992).
Saito, H., et al., “Immunological and virological predictors of outcome during interferon-α therapy of chronic hepatitis C”Journal of Viral Hepatitis, 7:64-74 (2000).
Shindo, M., et al., “Elevated Levels of 2′,5′-Oligoadenylate Synthetase Activity in Peripheral blood Mononuclear Cells and Serum during Acute Exacerbation of Chronic Hepatitis B”Hepatology, 9(5):715-719 (1989).
Trepo, C., “Genotype and viral load as prognostic indicators in the treatment of hepatitis C”Journal of Viral Hepatitis, 7:250-257 (2000).
Tyring, S.K., “Introduction to Clinical Uses of Interferons”Interferon: Principles and Medical Applications,Baron, et al. (eds.), Galveston TX, 1992.
Vallet, J.L., et al., “The Effect of Ovine Trophoblast Protein-One on Endometrial Protein Secretion and Cyclic Nucleotides”Biology of Reproduction, 37:1307-1316 (1987).
Whaley, A.E., et al., “Identification and Cellular Localization of Unique Interferon mRNA from Human Placenta”Journal of Biological Chemistry, 269(14):10864-10868 (1994).
Clayette, P., et al., “IFN—tau, a new interferon type I with antiretroviral activity,”Pathologie Biologiel, 47:4 553-559(1999).
Saez-Royuela, F., et al., “Treatment of Chronic Non-A Non-B Hepatitis with High Doses of Recombinant IFN-ALPHA or Recobinant IFN-TAU,” 40thAnnual Meeting of the American Association for the Study of Liver Diseases, Chicago, IL,Hepatology,10:4 646 (1989).
Liu Chih-Ping
Sokawa Yoshihiro
Mohr Judy M.
Mosher Mary E.
Pepgen Corporation
LandOfFree
Composition for treatment of and method of monitoring... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for treatment of and method of monitoring..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for treatment of and method of monitoring... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3541671